CrannMed was founded in 2018 with the aim of bringing together world-leading clinical, material science and delivery system experts to deliver the benefits of resorbable embolisation to patients worldwide.Permanent microspheres have existed for more than 20 years, and are routinely used to treat liver cancer, uterine fibroids and benign prostate hyperplasia. Resorbable microspheres can be used to treat a range of new indications where it is desirable to restore blood flow to the targeted area after the desired therapeutic effect has been achieved.These resorbable microspheres have new applications in areas such as Knee Osteoarthritis (KOA) and Adhesive Capsulitis (Frozen Shoulder) and have the potential to replace permanent beads in existing applications. As well as a range of resorbable microspheres, CrannMed is developing a next generation microcatheter to help improve access for these unique applications plus a flow directed delivery system to protect collateral vessels and eliminate non-target embolisation.